Search This Blog

Tuesday, June 25, 2013

Results of cardiovascular post-hoc meta-analysis examining CV events in adults with type 2 diabetes treated with linagliptin presented at ADA (NYSE:LLY)

Results of cardiovascular post-hoc meta-analysis examining CV events in adults with type 2 diabetes treated with linagliptin presented at ADA (NYSE:LLY)

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.